



	Selicrelumab	Dace-hz03C06.g6-2+1
EC50	0.09453	8.649

图 1



	Selicrelumab	Dace-hz03C06.g6-2+1
EC50	0.1159	0.009286

图 2




图 3



Tumor volume (mm3)
4000
3000
2000
1000
0
0
10
20
30
Days post tumor implantation
h-IgG, 3mg/kg
Dace-hz03C06.g6-2+1, 0.3mg/kg
Dace-hz03C06.g6-2+1, 1mg/kg
Dace-hz03C06.g6-2+1, 3mg/kg
Antibody dose i.p.

图 4



Body weight change(%)
40
30
20
10
0
-10
0
10
20
30
Days post tumor implantation
h-IgG, 3mg/kg
Dace-hz03C06.g6-2+1, 0.3mg/kg
Dace-hz03C06.g6-2+1, 1mg/kg
Dace-hz03C06.g6-2+1, 3mg/kg
Antibody dose i.p.

图 5



Tumor volume (mm3)
4000
3000
2000
1000
0
0
5
10
15
20
25
30
Days post tumor implantation
h-IgG, 10mg/kg
Dace-hz03C06.g6-2+2, 3mg/kg
Dace-hz03C06.g6-2+1, 3mg/kg
Atezolizumab, 10mg/kg
Antibody dose i.p.

图 6



Body weight change(%)
30
20
10
0
-10
0
10
20
30
Days post tumor implantation
h-IgG, 10mg/kg
Dace-hz03C06.g6-2+2, 3mg/kg
Dace-hz03C06.g6-2+1, 3mg/kg
Atezolizumab, 10mg/kg
Antibody dose i.p.

图 7



Tumor volume (mm3)
1200
900
600
300
0
0
5
10
15
20
25
30
Days post tumor implantation
h-IgG, 20mg/kg
Dace-hz03C06.g6-2+1, 10mg/kg
Dace-hz03C06.g6-2+1 dose i.p.

图 8



Body weight change(%)
30
20
10
0
-10
-20
0
10
20
30
40
Days post tumor implantation
h-IgG, 20mg/kg
Dace-hz03C06.g6-2+1, 10mg/kg
Dace-hz03C06.g6-2+1 dose i.p.

图 9



ALT
2000
1500
1000
400
300
200
100
U/L
Selicrelumab
Dace-hz03C06.g6-2+1
IgG1

图 10



AST
2000
1500
1000
400
300
200
100
U/L
Selicrelumab
Dace-hz03C06.g6-2+1
IgG1

图 11



TNF-α (Day 1)
Conc. (pg/ml)
1500
1200
900
600
300
0
Selicrelumab
Dace-hz03C06.g6-2+1
IgG1

图 12



IL-6 (Day 1)
Conc. (pg/ml)
120
100
80
60
40
20
0
Selicrelumab
Dace-hz03C06.g6-2+1
IgG1

图 13

双特异性抗体的分子示意图




图 14